Protease Inhibitor Current Events | Protease Inhibitor News
|
| Page
1 of
13 |
259 Results |
|
|
|
Sort By:
Page Views | Date |
Abacavir Could Play Important Future Role In Treatment Of Children With HIV-1 (p 733)
Results of the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial, published in this week's issue of THE LANCET, suggest an important future role for the drug abacavir in the treatment of children with HIV-1. Antiretroviral HIV-1 drug treatment for adults in more-developed countries usually involves combination therapy with two... view more... (2002-02-28)
Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
UCLA scientists, along with collaborators from Purdue University, have demonstrated that HIV protease inhibitors - crucial drugs for HIV treatment - block a cellular enzyme important for generating the structural scaffolding for the cell nucleus. view more (2007-07-17)
Drug combo may reduce protease inhibitor-related hardening of the arteries
Physiologists may have found a way to decrease the risk of hardening of the arteries that accompanies the long-term use of protease inhibitors, a class of drugs that has emerged as the most effective treatment against HIV and AIDS. view more (2006-09-05)
Arterial infusion using gabexate mesilate: Is it effective therapy for severe acute pancreatitis?
Severe acute pancreatitis (SAP) remains a lethal disease. It is defined as an inflammatory process of the pancreas with possible peripancreatic tissue and multi-organ involvement inducing multi-organ dysfunction syndrome (MODS) with an increased mortality rate. view more (2008-12-29)
Arterial infusion using gabexate mesilate: Is it effective therapy for severe acute pancreatitis?
Severe acute pancreatitis (SAP) remains a lethal disease. It is defined as an inflammatory process of the pancreas with possible peripancreatic tissue and multi-organ involvement inducing multi-organ dysfunction syndrome (MODS) with an increased mortality rate. view more (2008-12-30)
Curacyte scientists discover new anti-tumour agents
Curacyte AG, a Munich-based drug development company focused on novel treatments of inflammatory diseases, thrombotic disorders and cancer has announced today that its scientists have discovered a series of novel small molecule inhibitors of matriptase, a trypsin-like serine protease. Matriptase is an important mediator in the degradation of the... view more... (2003-06-17)
Compound has potential for new class of AIDS drugs
Researchers have developed what they believe is the first new mechanism in nearly 20 years for inhibiting a common target used to treat all HIV patients, which could eventually lead to a new class of AIDS drugs. view more (2008-05-15)
HIV-1 protease inhibitor induced oxidative stress in pancreatic B-cells: thymoquinone protection
Researchers at the Tulane University School of Medicine, New Orleans, Louisiana have discovered that the HIV-1 protease inhibitors (PIs), such as nelfinavir included in highly active antiretroviral therapy (HAART) regimen for the treatment of HIV-1 patients, induce deleterious effects on insulin secretion mediated through the oxidative stress... view more... (2009-03-26)
MU scientists 'see' how HIV matures into an infection
After improving the sensitivity of nuclear magnetic resonance (NMR), researchers at the University of Missouri actually watched the HIV-1 protease mature from an inactive form into an active infection. This process has never been directly visualized before. The findings appear today in the journal Nature. view more (2008-10-02)
Ethnic differences in response to HIV medicines
Researchers from the University of Massachusetts and the University of Pennsylvania have shown that race/ethnicity is a predictor of plasma lipids in patients with HIV-1 on HAART (highly active antiretroviral therapy). view more (2006-01-24)
Curacyte awarded a EUR1.2M grant to fund development of Factor Xa inhibitors
Curacyte AG, a Munich-based drug development company, has announced that its wholly owned subsidiary, Curacyte Chemistry GmbH based in Jena, has been awarded a EUR1.2M R&D grant from the German State of Thuringia's Corporate Technology Development Program. The grant will fund the lead optimization and pre-clinical development of the Company's... view more... (2003-10-29)
Enzyme inhibitors block replication Of SARS virus
Researchers have known since 2003 that a site on the virus is responsible for mediating proteases that allow the virus to replicate. Since then researchers have been testing protease inhibitors to lock up this site, known as SARS 3CLpro, and effectively stop the virus from infecting additional cells in the body. view more (2006-03-28)
HIV integrase inhibitor effective for patients beginning antiretroviral treatment
A member of a new class of antiretroviral drugs is safe and effective for patients beginning treatment against HIV, according to researchers who have completed a two-year multisite phase III clinical trial comparing it with standard antiretroviral drugs. view more (2009-08-03)
Specific Genotype Could Increase Resistance To HIV Drug Therapy (p 383)
A specific mutation of a gene which influences the expression of a glycoprotein transporter protein involved in the body's resistance to drugs and other toxins is detailed in a research letter in this week's issue of THE LANCET. Results of the study suggest that drug therapies used in treating HIV-1 infection (notably protease inhibitors ) may not... view more... (2001-08-01)
UCSF researchers identify new drug target for Kaposi's Sarcoma
UCSF researchers have identified a new potential drug target for the herpes virus that causes Kaposi's sarcoma, re-opening the possibility of using the class of drugs called protease inhibitors against the full herpes family of viruses, which for 20 years has been deemed too difficult to attain. view more (2009-07-30)
Researchers restore missing protein in rare genetic brain disorder
UCSF researchers have successfully used protease inhibitors to restore to normal levels a key protein involved in early brain development. Reduced levels of that protein have been shown to cause the rare brain disorder lissencephaly, which is characterized by brain malformations, seizures, severe mental retardation and very early death in human... view more... (2009-09-08)
Viral 'fitness' explains different resistance patterns to aids drugs
Some HIV medications lead to the development of drug-resistant HIV when patients take as few as two percent of their medications. view more (2006-01-11)
An effective method to study the pressure of the Sphincter of Oddi
The Sphincter of Oddi (SO) plays a vital role in maintaining the normal bile duct pressure, promoting gallbladder excretion and preventing from reflux. view more (2008-10-24)
UCSB researchers discover new biotechnology to identify
Researchers at UC Santa Barbara have developed a new biotechnology that enables scientists to identify and engineer protease substrates, giving them the means of crafting pharmaceuticals to outsmart disease. view more (2006-05-02)
Downstate researchers target multiple sclerosis
Researchers at SUNY Downstate Medical Center have developed a substance that inhibits the progress of multiple sclerosis (MS) in an animal model. The agent, a novel calpain inhibitor, can be administered orally. view more (2006-11-22)
|
|
| Page
1 of
13 |
259 Results |
|
|
|
Sort By:
Page Views | Date |
|
